Re: Ketogenic Diet - Path To Transformation?
At first glance I thought, 'Oh wow. Well, we already knew this, but at least it's getting some press!"
But upon closer reading, I noticed these two lines:
By selling nicotine addiction pills to the obese, pharmaceutical companies don't have to come up with any new formulas, and it opens up an entirely untapped market for what was likely a decreasingly profitable product (considering how the number of smokers goes down every year).
The study can be found here:
These vultures will never let a good 'epidemic' go to waste.
Gaby said:itellsya said:Just another article on sugar's addictive qualities - i don't think it's on sott and i'm not sure this study has been cited, i did check:
That's a good one for the database!
At first glance I thought, 'Oh wow. Well, we already knew this, but at least it's getting some press!"
But upon closer reading, I noticed these two lines:
Professor Selena Bartlett, a neuroscientist from the university's Institute of Health and Biomedical Innovation, says the research indicates that drugs used to treat nicotine addiction could be used to treat addiction to sugar.
"Our study found that Food and Drug Administration (FDA) approved drugs like varenicline, a prescription medication trading as Champix which treats nicotine addiction, can work the same way when it comes to sugar cravings."
By selling nicotine addiction pills to the obese, pharmaceutical companies don't have to come up with any new formulas, and it opens up an entirely untapped market for what was likely a decreasingly profitable product (considering how the number of smokers goes down every year).
The study can be found here:
Excess sugar consumption has been shown to contribute directly to weight gain, thus contributing to the growing worldwide obesity epidemic. Interestingly, increased sugar consumption has been shown to repeatedly elevate dopamine levels in the nucleus accumbens (NAc), in the mesolimbic reward pathway of the brain similar to many drugs of abuse. We report that varenicline, an FDA-approved nicotinic acetylcholine receptor (nAChR) partial agonist that modulates dopamine in the mesolimbic reward pathway of the brain, significantly reduces sucrose consumption, especially in a long-term consumption paradigm. Similar results were observed with other nAChR drugs, namely mecamylamine and cytisine. Furthermore, we show that long-term sucrose consumption increases α4β2 * and decreases α6β2* nAChRs in the nucleus accumbens, a key brain region associated with reward. Taken together, our results suggest that nAChR drugs such as varenicline may represent a novel treatment strategy for reducing sugar consumption.
These vultures will never let a good 'epidemic' go to waste.